Polymyalgia rheumatica (PMR) is an inflammatory condition, but it doesn’t fit neatly into the autoimmune category. While it was long grouped with autoimmune diseases, current evidence points more toward it being “autoinflammatory,” meaning the body’s first-line immune defenses overreact rather than the immune system mistakenly attacking specific tissues with targeted antibodies. The distinction matters because it shapes how the disease is understood, diagnosed, and treated.
Why PMR Doesn’t Fit the Autoimmune Label
Autoimmune diseases like rheumatoid arthritis and lupus share a hallmark: the adaptive immune system produces antibodies that target the body’s own tissues. These autoantibodies can be measured in blood tests and often play a direct role in causing damage. In PMR, no such antibodies have been identified. There are no disease-specific autoantibodies that carry a diagnostic or pathogenic role, which is one of the strongest arguments against calling it a true autoimmune disease.
Instead, PMR appears to be driven largely by the innate immune system, the older, less targeted branch of immunity that responds quickly to perceived threats without the precision of antibodies. One way researchers think about this is through the “immunological continuum model,” which places all immune-mediated diseases on a spectrum. On one end sit purely autoinflammatory conditions driven by innate immunity. On the other sit classic autoimmune diseases driven by adaptive immunity. PMR lands closer to the autoinflammatory side, though it likely has some mixed features.
The Role of Inflammation in PMR
What drives PMR symptoms is a surge in systemic inflammation, particularly involving a signaling molecule called interleukin-6 (IL-6). IL-6 levels are elevated in the blood of people with PMR and correlate directly with how active the disease is. This molecule triggers the liver to produce acute-phase proteins, which is why blood markers of inflammation (ESR and CRP) spike so dramatically. In fact, elevated inflammatory markers are one of the most consistent features of PMR and are built into the diagnostic criteria.
There is also involvement of certain immune cells called Th17 cells, which are found in higher numbers in the blood of people with PMR compared to healthy individuals. These cells produce their own inflammatory signals, adding fuel to the cycle. The precursor cells that give rise to Th17 cells in PMR patients produce significantly more inflammatory compounds than those from healthy people, and IL-6 plays a central role in pushing those precursor cells to become active Th17 cells.
Who Gets PMR
PMR is overwhelmingly a disease of older adults. The average age of onset is just over 70, and it essentially never occurs before age 50. About 75% of patients are women. It’s most common in people of northern European ancestry, though it can occur in any ethnic group.
There is a genetic component. Certain variants of immune system genes (in the HLA-DRB1 family) have been linked to PMR susceptibility and to more severe disease courses. One study found that carrying specific versions of what’s called the “rheumatoid epitope” encoded by non-DR4 genes increased the risk of relapse nearly threefold. However, PMR doesn’t run in families in the obvious way that some autoimmune diseases do, and genetics alone don’t explain who develops it.
How PMR Is Diagnosed
Because there’s no specific autoantibody to test for, diagnosing PMR relies on a combination of symptoms and blood work. The classic presentation is bilateral pain and stiffness in the shoulders, neck, and hips that comes on relatively quickly, often over days to weeks. Morning stiffness lasting more than 45 minutes is typical.
Blood tests look for elevated inflammatory markers. The traditional threshold is an erythrocyte sedimentation rate (ESR) of 40 mm/h or higher and a C-reactive protein (CRP) above 6 mg/L. These numbers reflect the body-wide inflammation that PMR causes. That said, a small number of people with PMR have normal inflammatory markers at diagnosis, so the blood tests alone don’t rule it in or out. Doctors also need to exclude other conditions that mimic PMR, including rheumatoid arthritis, infection, and cancer.
The Connection to Giant Cell Arteritis
Between 16 and 21% of people with PMR also have giant cell arteritis (GCA), a condition where inflammation targets the walls of large blood vessels, particularly the arteries near the temples. A recent meta-analysis put the prevalence of subclinical GCA in new-onset PMR even higher, at around 23%. The two conditions share underlying inflammatory mechanisms, and GCA can develop before, during, or after PMR.
The warning signs of GCA in someone with PMR include new or unusual headaches, tenderness of the scalp, jaw pain while chewing, and any changes in vision. Large-vessel GCA is harder to catch because its symptoms are less specific: fatigue, unexplained weight loss, and persistent fever. GCA requires more aggressive treatment because it can lead to permanent vision loss, so recognizing these symptoms early is important.
Treatment and What to Expect
Corticosteroids remain the primary treatment. Guidelines recommend starting with prednisone at 15 to 20 mg daily, though research suggests lower-weight patients may do well starting below 15 mg. Most people feel dramatically better within days. Remission is typically defined as at least 70% improvement in symptoms along with normalization of inflammatory markers within the first month.
The challenge is getting off steroids. Doses are tapered gradually, and this is where things get difficult. About 43% of patients experience at least one relapse within the first year of treatment. More than half of all patients relapse at some point during steroid tapering. As a result, steroid use stretches far longer than anyone would prefer: 77% of patients are still taking steroids at the one-year mark, 51% at two years, and 25% at five years. If no relapses occur, steroid treatment might wrap up around 12 months. One flare pushes that closer to 15 months. After stopping steroids entirely, recurrences can still happen, with rates between 5 and 37% in the months that follow.
Long-term steroid use brings its own problems, including bone thinning, weight gain, elevated blood sugar, and increased infection risk. Traditional alternatives like methotrexate have not shown clear benefit. A newer option targets the IL-6 pathway directly. Sarilumab, a biologic that blocks the IL-6 receptor, was tested in a phase 3 trial for people with PMR who relapsed during steroid tapering. Patients receiving sarilumab with a rapid 14-week prednisone taper had a median cumulative steroid dose of 777 mg over a year, compared to 2,044 mg for those on a standard 52-week taper with placebo. That’s a reduction of more than 60% in total steroid exposure, which translates to meaningfully fewer side effects over time.
Living With PMR Long Term
PMR is not a lifelong disease for most people, but it lasts longer than many expect. The relapse rates mean that the path from diagnosis to being medication-free is rarely a straight line. Flares during tapering are common and don’t mean treatment has failed. They typically require a temporary bump in steroid dose followed by a slower taper.
Understanding that PMR is primarily an autoinflammatory process, not an autoimmune attack on specific organs, can be reassuring. It doesn’t cause joint destruction the way rheumatoid arthritis does. It doesn’t produce the organ damage seen in lupus. The inflammation is real and can be debilitating, but it’s also highly treatable, and for most people, it eventually resolves. The main practical concern is managing the side effects of the steroids needed to control it, which is why the development of steroid-sparing biologics represents a meaningful shift in how the disease can be managed.